ce-20210722
0001306830false00013068302021-07-222021-07-220001306830us-gaap:CommonStockMember2021-07-222021-07-220001306830ce:SeniorUnsecuredNotesDue2023Member2021-07-222021-07-220001306830ce:SeniorUnsecuredNotesDue2025Member2021-07-222021-07-220001306830ce:SeniorUnsecuredNotesDue2027Member2021-07-222021-07-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 22, 2021
CELANESE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-3241098-0420726
   
(State or other jurisdiction
of incorporation)		(Commission File
Number)		(IRS Employer
Identification No.)
222 West Las Colinas Blvd. Suite 900N, Irving, TX 75039
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (972) 443-4000

N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s) Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per shareCEThe New York Stock Exchange
1.125% Senior Notes due 2023CE /23The New York Stock Exchange
1.250% Senior Notes due 2025CE /25The New York Stock Exchange
2.125% Senior Notes due 2027CE /27The New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

1

Item 2.02 Results of Operations and Financial Condition
On July 22, 2021, Celanese Corporation (the "Company") issued a press release reporting the financial results for its second quarter 2021. A copy of the press release is attached to this Current Report on Form 8-K ("Current Report") as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 2.02 disclosure. Each non-US GAAP financial measure appearing in the press release is accompanied by the most directly comparable US GAAP financial measure and is reconciled to the most comparable US GAAP financial measure in Exhibit 99.2, which includes other supplemental information of interest to investors, analysts and other parties, including the reasons why management believes such Non-US GAAP financial measures provide useful information to investors, and which is incorporated herein solely for purposes of this Item 2.02 disclosure.
Item 9.01 Financial Statements and Exhibits
(d) The following exhibits are being furnished herewith:
Exhibit
Number		 
Description
  
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document contained in Exhibit 101).
*In connection with the disclosure set forth in Item 2.02, the information in this Current Report, including the exhibits attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.
2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    
 
CELANESE CORPORATION
 
 By:/s/ MICHAEL R. SULLIVAN
 Name: Michael R. Sullivan
 Title:  Vice President, Deputy General Counsel and Assistant Corporate Secretary 
 
Date:July 22, 2021
3

Exhibit 99.1
celogoa02a01a10a01a02a01a36a.jpg
Celanese Corporation
222 West Las Colinas Blvd.
Suite 900N
Irving, Texas 75039


Celanese Corporation Reports Second Quarter 2021 Earnings;
Raises Full Year Financial Outlook


Dallas, July 22, 2021: Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today reported second quarter GAAP diluted earnings per share of $4.81, the second highest in the Company's history, and highest-ever adjusted earnings per share of $5.02. The Company reported record net sales of $2.2 billion for the quarter with sequential pricing and volume increases of 18 percent and 4 percent, respectively. Actions over the past year, including accelerated turnarounds as well as enhanced sourcing and commercial flexibility, positioned the Company to meet elevated post-pandemic demand in 2021 and to deliver record performance during the second quarter. Engineered Materials and the Acetyl Chain successfully offset continued raw material inflation to drive consolidated operating profit of $567 million and adjusted EBIT of $691 million.
The recently announced acquisition of Santoprene™ and ongoing capital projects within the Acetyl Chain and Engineered Materials position the Company to further raise its future base earnings and deliver sustained shareholder value. During the quarter, the Company returned $326 million of cash to shareholders in the form of share repurchases and dividends.


1

Second Quarter 2021 Financial Highlights:
Three Months Ended
June 30,
2021		March 31,
2021		June 30,
2020
(unaudited)
(In $ millions, except per share data)
Net Sales
Engineered Materials682 645 420 
Acetate Tow138 119 127 
Acetyl Chain1,409 1,056 662 
Intersegment Eliminations(31)(22)(16)
Total2,198 1,798 1,193 
Operating Profit (Loss)
Engineered Materials123 130 (13)
Acetate Tow24 16 31 
Acetyl Chain516 251 121 
Other Activities(96)(71)(56)
Total567 326 83 
Net Earnings (Loss)
540 323 109 
Adjusted EBIT(1)
Engineered Materials161 160 40 
Acetate Tow62 61 64 
Acetyl Chain514 282 116 
Other Activities(46)(21)(21)
Total691 482 199 
Equity Earnings and Dividend Income, Other Income (Expense)
Engineered Materials32 25 26 
Acetate Tow37 41 32 
Operating EBITDA(1)
781 570 285 
Diluted EPS - continuing operations$4.81 $2.83 $0.93 
Diluted EPS - total$4.77 $2.82 $0.90 
Adjusted EPS(1)
$5.02 $3.46 $1.30 
Net cash provided by (used in) investing activities177 98 (181)
Net cash provided by (used in) financing activities(344)(371)(232)
Net cash provided by (used in) operating activities427 116 379 
Free cash flow(1)
309 19 283 
_____________________________
(1)See "Non-US GAAP Financial Measures" below.
2


Recent Highlights:
•Announced the signing of a definitive agreement to acquire the Santoprene™ TPV elastomers business of Exxon Mobil Corporation for $1.15 billion, strengthening the existing elastomers portfolio and bringing a wider range of functionalized solutions into targeted growth areas.
•Announced the acquisition of certain technology and sales agreements relating to the production of polyacetal (POM) products from Grupa Azoty S.A. of Poland, following their decision to discontinue POM manufacturing.
•Announced an expansion of the Florence, Kentucky research and development center with the addition of a pharmaceutical drug delivery lab, supporting programs, and products for long-acting, controlled release drug delivery.
•Increased the outstanding share repurchase authorization by $1.0 billion, approved by the Board of Directors in July. As of June 30, 2021, the Company had $563 million remaining under the previous authorization.

Second Quarter 2021 Business Segment Overview
Engineered Materials
Engineered Materials reported record net sales of $682 million in the second quarter, primarily due to a 7 percent sequential pricing increase. Pricing expanded during the second quarter, driven by the commercial team's implementation of pricing initiatives in line with raw material inflation, as well as improved mix. Volume was stable compared to the prior period, as the business proactively navigated significant raw material constraints and offset a sequential decline in global auto builds amid semiconductor supply shortages. Engineered Materials generated second quarter GAAP operating profit of $123 million and adjusted EBIT of $161 million. GAAP operating profit and adjusted EBIT margins were 18 percent and 24 percent, respectively. Affiliate earnings increased by $7 million during the second quarter, primarily due to improved performance by Ibn Sina.
Acetyl Chain
The Acetyl Chain generated record net sales of $1.4 billion, a 33 percent increase from the prior quarter due to sequential increases in pricing and volume. Pricing increased 27 percent, primarily due to elevated acetic acid pricing in China amid tightened industry utilization. Volume increased 7 percent sequentially driven by availability of incremental Acetyl Chain production capacity and continued strong demand across most end-markets and regions. The Company successfully resolved raw material constraints and brought its Clear Lake, Texas acetic acid facility back to full operating rates during the second quarter. The Acetyl Chain generated record GAAP operating profit and adjusted EBIT of $516 million and $514 million, respectively, during the second quarter. The business also delivered record operating profit margin of 37 percent and adjusted EBIT margin of 36 percent, expansions of 1,280 and 980 basis points, respectively, over the prior quarter.
3

Acetate Tow
Acetate Tow recorded net sales of $138 million during the second quarter, which reflected a sequential volume increase of 16 percent and stable pricing. Volume expansion in the second quarter was primarily attributable to timing of customer orders, which were delayed in the prior quarter due to Winter Storm Uri. Higher volume offset the impact of elevated natural gas and acetyls costs to contribute to second quarter GAAP operating profit of $24 million and adjusted EBIT of $62 million. Dividends from affiliates in the second quarter were $37 million, lower sequentially due to the timing of dividend payments.
Cash Flow and Tax
The Company generated second quarter operating cash flow of $427 million and free cash flow of $309 million. Capital expenditures in the second quarter were $110 million and included expenditures for expansion and productivity projects within the Acetyl Chain and Engineered Materials businesses. The Company returned $326 million in cash to shareholders during the second quarter, including $250 million of share repurchases and $76 million of dividends.
The effective US GAAP tax rate of 18 percent in the second quarter was lower in comparison to 24 percent in the same quarter of last year, primarily due to non-recurring adjustments to uncertain tax positions in the prior year, partially offset by increased earnings in high tax jurisdictions. During the second quarter, the Company increased the full year adjusted tax rate from 14 percent to 15 percent, primarily due to the increase in earnings in higher tax jurisdictions. This resulted in an adjusted tax rate of 16 percent for the quarter.
Outlook
"Our record performance this quarter reflected the global positions and unique optionality within our businesses to meet elevated customer demand despite significant sourcing and supply chain constraints that persist," said Lori Ryerkerk, chairman and chief executive officer. "With very strong earnings and cash generation across 2021, we are investing in future growth via organic opportunities within our businesses, disciplined M&A like the Santoprene acquisition, and share repurchases. Our teams' proactive response to the ongoing global supply chain constraints and inflationary backdrop have positioned us well as we enter the second half of 2021. We anticipate that continued moderation in Acetyl Chain industry pricing as the year progresses will be partially offset by strong fundamental demand across our businesses and modest continued sequential earnings momentum in Engineered Materials. As a result, we expect third quarter 2021 adjusted earnings of $4.50 to $4.75 per share and full year 2021 adjusted earnings of $16.50 to $17.00 per share."
The Company is unable to reconcile forecasted adjusted earnings per share growth to US GAAP diluted earnings per share without unreasonable efforts because a forecast of Certain Items, such as mark-to-market pension gains/losses, is not practical. For more information, see "Non-GAAP Financial Measures" below.
The Company's prepared remarks related to the second quarter will be posted on its website at investors.celanese.com under Financial Information/Financial Document Library on July 22, 2021. Information about Non-US GAAP measures is included in a Non-US GAAP Financial Measures and Supplemental Information document posted on our investor relations website under Financial Information/Non-GAAP Financial Measures. See also "Non-GAAP Financial Measures" below.
4

Contacts:
Investor RelationsMedia - U.S.Media - Europe
Brandon AyacheTravis JacobsenPetra Czugler
Phone: +1 972 443 8509Phone: +1 972 443 3750Phone: +49 69 45009 1206
[email protected][email protected][email protected]
Celanese Corporation is a global chemical leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese's global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,700 employees worldwide and had 2020 net sales of $5.7 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com or our blog at www.celaneseblog.com.

Forward-Looking Statements
This release may contain "forward-looking statements," which include information concerning the Company's plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied in the forward-looking statements contained in this release. These risks and uncertainties include, among other things: the extent to which the COVID-19 pandemic continues to adversely impact the economic environment, market demand and our operations, as well as the pace of any economic recovery; changes in general economic, business, political and regulatory conditions in the countries or regions in which we operate; the length and depth of product and industry business cycles, particularly in the automotive, electrical, mobility, textiles, medical, electronics and construction industries; changes in the price and availability of raw materials, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, wood pulp and fuel oil and the prices for electricity and other energy sources; the ability to pass increases in raw material prices on to customers or otherwise improve margins through price increases; the ability to maintain plant utilization rates and to implement planned capacity additions and expansions as well as facility turnarounds; the ability to reduce or maintain their current levels of production costs and to improve productivity by implementing technological improvements to existing plants; the ability to identify desirable potential acquisition targets and to complete acquisition or investment transactions consistent with the Company's strategy; the ability to identify and execute on other attractive investment opportunities towards which to deploy capital; increased price competition and the introduction of competing products by other companies; market acceptance of our products and technology; compliance and other costs and potential disruption or interruption of production or operations due to accidents, interruptions in sources of raw materials, cyber security incidents, terrorism or political unrest, public health crises (including, but not limited to, the COVID-19 pandemic); other unforeseen events or delays in construction or operation of facilities, including as a result of geopolitical conditions, the occurrence of acts of war or terrorist incidents or as a result of weather or natural disasters or other crises including public health crises; the ability to obtain governmental approvals and to construct facilities on terms and schedules acceptable to the Company; changes in the degree of intellectual property and other legal protection afforded to our products or technologies, or the theft of such intellectual property; potential liability for remedial actions and increased costs under existing or future environmental, health and safety regulations, including those relating to climate change; potential liability resulting from pending or future litigation, or from changes in the laws, regulations or policies of governments or other governmental activities in the countries in which we operate; changes in currency exchange rates and interest rates; our level of indebtedness, which could diminish our ability to raise additional capital to fund operations or limit our ability to react to changes in the economy or the chemicals industry; tax rates and changes thereto; our ability to obtain regulatory approval for, and satisfy closing conditions to, any transactions described herein; and various other factors discussed from time to time in the Company's filings with the Securities and Exchange Commission.

The extent to which COVID-19 will adversely impact our business, financial condition and results of operations will depend on numerous evolving factors, which are highly uncertain, rapidly changing and cannot be predicted, including: the extent of any resurgence in infections and the spread of the disease, and the effectiveness of any vaccines; additional governmental, business and individual actions to contain the spread of the outbreak, including social distancing, work-at-home, stay-at-home and shelter-in-place orders and shutdowns, travel restrictions and quarantines; the extent to which these conditions depress economic activity generally and demand for our products specifically and affect the financial markets; the effect of the outbreak on our customers, suppliers, supply chain and other business partners; our ability during the outbreak to provide our products and services, including the health and well-being of our employees; business disruptions caused by actual or potential plant, workplace and office closures; the risk that we could be exposed to liability, negative publicity or reputational harm related to any incidents of actual or perceived transmission of COVID-19 among employees at our facilities; the ability of our customers to pay for our products and services during and following the outbreak; the impact of the outbreak on the financial markets and economic activity generally; our ability to access usual sources of liquidity on reasonable terms; and our ability to comply with the financial covenant in our Credit Agreement if a material and prolonged economic downturn results in increased indebtedness or substantially lower EBITDA.

Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

Non-GAAP Financial Measures
Presentation
This document presents the Company's three business segments, Engineered Materials, Acetate Tow and Acetyl Chain.
5

Use of Non-US GAAP Financial Information
This release uses the following Non-US GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, adjusted earnings per share and free cash flow. These measures are not recognized in accordance with US GAAP and should not be viewed as an alternative to US GAAP measures of performance or liquidity. The most directly comparable financial measure presented in accordance with US GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin is operating margin; for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; and for free cash flow is net cash provided by (used in) operations.
Definitions of Non-US GAAP Financial Measures
•Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8 of our Non-US GAAP Financial Measures and Supplemental Information document). We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales.
•Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization.
•Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.
Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a of our Non-US GAAP Financial Measures and Supplemental Information document summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.
•Free cash flow is a liquidity measure used by the Company and is defined by the Company as cash flow from operations, less capital expenditures on property, plant and equipment, and adjusted for capital contributions from or distributions to Mitsui & Co., Ltd. ("Mitsui") related to our methanol joint venture, Fairway Methanol LLC ("Fairway").
    Reconciliation of Non-US GAAP Financial Measures
Reconciliations of the Non-US GAAP financial measures used in this press release to the comparable US GAAP financial measure, together with information about the purposes and uses of Non-US GAAP financial measures, are included in our Non-US GAAP Financial Measures and Supplemental Information document filed as an exhibit to our Current Report on Form 8-K filed with the SEC on or about July 22, 2021 and also available on our website at investors.celanese.com under Financial Information/Financial Document Library.
Results Unaudited
The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.
Supplemental Information
Additional information about our prior period performance is included in our Quarterly Reports on Form 10-Q and in our Non-US GAAP Financial Measures and Supplemental Information document.
6

Consolidated Statements of Operations - Unaudited
Three Months Ended
June 30,
2021		March 31,
2021		June 30,
2020
(In $ millions, except share and per share data)
Net sales2,198 1,798 1,193 
Cost of sales(1,437)(1,313)(951)
Gross profit761 485 242 
Selling, general and administrative expenses(161)(137)(114)
Amortization of intangible assets(5)(6)(6)
Research and development expenses(22)(20)(18)
Other (charges) gains, net(3)6 (21)
Foreign exchange gain (loss), net(3)3 1 
Gain (loss) on disposition of businesses and assets, net— (5)(1)
Operating profit (loss)567 326 83 
Equity in net earnings (loss) of affiliates37 29 31 
Non-operating pension and other postretirement employee benefit (expense) income
38 38 27 
Interest expense(24)(25)(27)
Interest income4 1 1 
Dividend income - equity investments37 42 32 
Other income (expense), net1 (2)— 
Earnings (loss) from continuing operations before tax660 409 147 
Income tax (provision) benefit(116)(85)(35)
Earnings (loss) from continuing operations544 324 112 
Earnings (loss) from operation of discontinued operations(6)(1)(4)
Income tax (provision) benefit from discontinued operations2 — 1 
Earnings (loss) from discontinued operations(4)(1)(3)
Net earnings (loss)540 323 109 
Net (earnings) loss attributable to noncontrolling interests(2)(1)(2)
Net earnings (loss) attributable to Celanese Corporation538 322 107 
Amounts attributable to Celanese Corporation 
Earnings (loss) from continuing operations542 323 110 
Earnings (loss) from discontinued operations(4)(1)(3)
Net earnings (loss)538 322 107 
Earnings (loss) per common share - basic
Continuing operations4.83 2.85 0.93 
Discontinued operations(0.04)(0.01)(0.03)
Net earnings (loss) - basic4.79 2.84 0.90 
Earnings (loss) per common share - diluted
Continuing operations4.81 2.83 0.93 
Discontinued operations(0.04)(0.01)(0.03)
Net earnings (loss) - diluted4.77 2.82 0.90 
Weighted average shares (in millions) 
Basic112.3 113.5 118.3 
Diluted112.8 114.0 118.8 
7

Consolidated Balance Sheets - Unaudited
As of
June 30,
2021		As of
December 31,
2020
(In $ millions)
ASSETS
Current Assets
Cash and cash equivalents1,054 955 
Trade receivables - third party and affiliates, net1,218 792 
Non-trade receivables, net570 450 
Inventories1,118 978 
Marketable securities29 533 
Other assets72 55 
Total current assets4,061 3,763 
Investments in affiliates818 820 
Property, plant and equipment, net3,922 3,939 
Operating lease right-of-use assets215 232 
Deferred income taxes257 259 
Other assets500 411 
Goodwill1,143 1,166 
Intangible assets, net304 319 
Total assets11,220 10,909 
LIABILITIES AND EQUITY  
Current Liabilities  
Short-term borrowings and current installments of long-term debt - third party and affiliates
500 496 
Trade payables - third party and affiliates998 797 
Other liabilities531 680 
Income taxes payable100 — 
Total current liabilities2,129 1,973 
Long-term debt, net of unamortized deferred financing costs3,156 3,227 
Deferred income taxes526 509 
Uncertain tax positions260 240 
Benefit obligations611 643 
Operating lease liabilities181 208 
Other liabilities200 214 
Commitments and Contingencies 
Stockholders' Equity 
Treasury stock, at cost(4,993)(4,494)
Additional paid-in capital292 257 
Retained earnings8,797 8,091 
Accumulated other comprehensive income (loss), net(298)(328)
Total Celanese Corporation stockholders' equity3,798 3,526 
Noncontrolling interests359 369 
Total equity4,157 3,895 
Total liabilities and equity11,220 10,909 
8
celaneseimagea20.jpg
Exhibit 99.2
Non-US GAAP Financial Measures and Supplemental Information
July 22, 2021
In this document, the terms the "Company," "we" and "our" refer to Celanese Corporation and its subsidiaries on a consolidated basis.
Purpose
The purpose of this document is to provide information of interest to investors, analysts and other parties including supplemental financial information and reconciliations and other information concerning our use of non-US GAAP financial measures. This document is updated quarterly.
Presentation
This document presents the Company's three business segments, Engineered Materials, Acetate Tow and Acetyl Chain.
Use of Non-US GAAP Financial Measures
From time to time, management may publicly disclose certain numerical "non-GAAP financial measures" in the course of our earnings releases, financial presentations, earnings conference calls, investor and analyst meetings and otherwise. For these purposes, the Securities and Exchange Commission ("SEC") defines a "non-GAAP financial measure" as a numerical measure of historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that effectively exclude amounts, included in the most directly comparable measure calculated and presented in accordance with US GAAP, and vice versa for measures that include amounts, or are subject to adjustments that effectively include amounts, that are excluded from the most directly comparable US GAAP measure so calculated and presented. For these purposes, "GAAP" refers to generally accepted accounting principles in the United States.
Non-GAAP financial measures disclosed by management are provided as additional information to investors, analysts and other parties because the Company believes them to be important supplemental measures for assessing our financial and operating results and as a means to evaluate our financial condition and period-to-period comparisons. These non-GAAP financial measures should be viewed as supplemental to, and should not be considered in isolation or as alternatives to, net earnings (loss), operating profit (loss), operating margin, cash flow from operating activities (together with cash flow from investing and financing activities), earnings per share or any other US GAAP financial measure. These non-GAAP financial measures should be considered within the context of our complete audited and unaudited financial results for the given period, which are available on the Financial Information/Financial Document Library page of our website, investors.celanese.com. The definition and method of calculation of the non-GAAP financial measures used herein may be different from other companies' methods for calculating measures with the same or similar titles. Investors, analysts and other parties should understand how another company calculates such non-GAAP financial measures before comparing the other company's non-GAAP financial measures to any of our own. These non-GAAP financial measures may not be indicative of the historical operating results of the Company nor are they intended to be predictive or projections of future results.
Pursuant to the requirements of SEC Regulation G, whenever we refer to a non-GAAP financial measure, we will also present in this document, in the presentation itself or on a Form 8-K in connection with the presentation on the Financial Information/Financial Document Library page of our website, investors.celanese.com, to the extent practicable, the most directly comparable financial measure calculated and presented in accordance with GAAP, along with a reconciliation of the differences between the non-GAAP financial measure we reference and such comparable GAAP financial measure.
This document includes definitions and reconciliations of non-GAAP financial measures used from time to time by the Company.
Specific Measures Used
This document provides information about the following non-GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, operating EBITDA margin, operating profit (loss) attributable to Celanese Corporation, adjusted earnings per share, net debt, free cash flow and return on invested capital (adjusted). The most directly comparable financial measure presented in accordance with US GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin and operating EBITDA margin is operating margin; for operating profit (loss) attributable to Celanese Corporation is operating profit (loss); for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; for net debt
1
celaneseimagea20.jpg
is total debt; for free cash flow is net cash provided by (used in) operations; and for return on invested capital (adjusted) is net earnings (loss) attributable to Celanese Corporation divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation stockholders' equity.
Definitions
•Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to Table 8). We believe that adjusted EBIT provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of unusual, non-operational or restructuring-related activities that affect comparability. Our management recognizes that adjusted EBIT has inherent limitations because of the excluded items. Adjusted EBIT is one of the measures management uses for planning and budgeting, monitoring and evaluating financial and operating results and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales. Adjusted EBIT margin has the same uses and limitations as Adjusted EBIT.
•Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization. We believe that Operating EBITDA provides transparent and useful information to investors, analysts and other parties in evaluating our operating performance relative to our peer companies. Operating EBITDA margin is defined by the Company as Operating EBITDA divided by net sales. Operating EBITDA margin has the same uses and limitations as Operating EBITDA.
•Operating profit (loss) attributable to Celanese Corporation is defined by the Company as operating profit (loss), less earnings (loss) attributable to noncontrolling interests ("NCI"). We believe that operating profit (loss) attributable to Celanese Corporation provides transparent and useful information to management, investors, analysts and other parties in evaluating our core operational performance. Operating margin attributable to Celanese Corporation is defined by the Company as operating profit (loss) attributable to Celanese Corporation divided by net sales. Operating margin attributable to Celanese Corporation has the same uses and limitations as Operating profit (loss) attributable to Celanese Corporation.
•Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We believe that adjusted earnings per share provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of the above stated items that affect comparability and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.
Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. Table 3a summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.
2
celaneseimagea20.jpg
•Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operations, less capital expenditures on property, plant and equipment, and adjusted for capital contributions from or distributions to Mitsui & Co., Ltd. ("Mitsui") related to our methanol joint venture, Fairway Methanol LLC ("Fairway"). We believe that free cash flow provides useful information to management, investors, analysts and other parties in evaluating the Company's liquidity and credit quality assessment because it provides an indication of the long-term cash generating ability of our business. Although we use free cash flow as a measure to assess the liquidity generated by our business, the use of free cash flow has important limitations, including that free cash flow does not reflect the cash requirements necessary to service our indebtedness, lease obligations, unconditional purchase obligations or pension and postretirement funding obligations.
•Net debt is defined by the Company as total debt less cash and cash equivalents. We believe that net debt provides useful information to management, investors, analysts and other parties in evaluating changes to the Company's capital structure and credit quality assessment.
•Return on invested capital (adjusted) is defined by the Company as adjusted EBIT, tax effected using the adjusted tax rate, divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation stockholders' equity. We believe that return on invested capital (adjusted) provides useful information to management, investors, analysts and other parties in order to assess our income generation from the point of view of our stockholders and creditors who provide us with capital in the form of equity and debt and whether capital invested in the Company yields competitive returns.
Supplemental Information
Supplemental Information we believe to be of interest to investors, analysts and other parties includes the following:
•Net sales for each of our business segments and the percentage increase or decrease in net sales attributable to price, volume, currency and other factors for each of our business segments.
•Cash dividends received from our equity investments.
•For those consolidated ventures in which the Company owns or is exposed to less than 100% of the economics, the outside stockholders' interests are shown as NCI. Beginning in 2014, this includes Fairway for which the Company's ownership percentage is 50%. Amounts referred to as "attributable to Celanese Corporation" are net of any applicable NCI.
Results Unaudited
The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.
3
celaneseimagea20.jpg
Table 1
Adjusted EBIT and Operating EBITDA - Reconciliation of Non-GAAP Measures - Unaudited
Q2 '21Q1 '212020Q4 '20Q3 '20Q2 '20Q1 '20
(In $ millions)
Net earnings (loss) attributable to Celanese Corporation
538 322 1,985 1,453 207 107 218 
(Earnings) loss from discontinued operations
4 1 12 — 2 3 7 
Interest income(4)(1)(6)(2)(1)(1)(2)
Interest expense24 25 109 26 28 27 28 
Income tax provision (benefit)116 85 247 117 30 35 65 
Certain Items attributable to Celanese Corporation (Table 8)
13 50 (1,216)(1,294)24 28 26 
Adjusted EBIT691 482 1,131 300 290 199 342 
Depreciation and amortization expense(1)
90 88 344 87 88 86 83 
Operating EBITDA781 570 1,475 387 378 285 425 
Q2 '21Q1 '212020Q4 '20Q3 '20Q2 '20Q1 '20
(In $ millions)
Engineered Materials1 2 5 2 1 — 2 
Acetate Tow— — — — — — — 
Acetyl Chain— — 1 — — 1 — 
Other Activities(2)
— — — — — — — 
Accelerated depreciation and amortization expense
1 2 6 2 1 1 2 
Depreciation and amortization expense(1)
90 88 344 87 88 86 83 
Total depreciation and amortization expense
91 90 350 89 89 87 85 
______________________________
(1)Excludes accelerated depreciation and amortization expense as detailed in the table above, which amounts are included in Certain Items above.
(2)Other Activities includes corporate Selling, general and administrative ("SG&A") expenses, the results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).
4
Table 2 - Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited
celaneseimagea20.jpg
Q2 '21Q1 '212020Q4 '20Q3 '20Q2 '20Q1 '20
(In $ millions, except percentages)
Operating Profit (Loss) / Operating Margin
Engineered Materials123 18.0 %130 20.2 %235 11.3 %62 10.8 %84 16.0 %(13)(3.1)%102 18.1 %
Acetate Tow24 17.4 %16 13.4 %118 22.7 %30 22.4 %30 23.3 %31 24.4 %27 20.9 %
Acetyl Chain(1)
516 36.6 %251 23.8 %563 17.9 %186 20.4 %121 15.6 %121 18.3 %135 16.9 %
Other Activities(2)
(96)(71)(252)(75)(51)(56)(70)
Total567 25.8 %326 18.1 %664 11.7 %203 12.8 %184 13.0 %83 7.0 %194 13.3 %
Less: Net Earnings (Loss) Attributable to NCI(1)
2 1 7 1 2 2 2 
Operating Profit (Loss) Attributable to Celanese Corporation565 25.7 %325 18.1 %657 11.6 %202 12.7 %182 12.9 %81 6.8 %192 13.2 %
Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation
Engineered Materials123 18.0 %130 20.2 %235 11.3 %62 10.8 %84 16.0 %(13)(3.1)%102 18.1 %
Acetate Tow24 17.4 %16 13.4 %118 22.7 %30 22.4 %30 23.3 %31 24.4 %27 20.9 %
Acetyl Chain(1)
514 36.5 %250 23.7 %556 17.7 %185 20.3 %119 15.3 %119 18.0 %133 16.6 %
Other Activities(2)
(96)(71)(252)(75)(51)(56)(70)
Total565 25.7 %325 18.1 %657 11.6 %202 12.7 %182 12.9 %81 6.8 %192 13.2 %
Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation
Engineered Materials32 25 115 15 21 26 53 
Acetate Tow37 41 126 29 28 32 37 
Acetyl Chain2 2 5 2 2 — 1 
Other Activities(2)
4 1 19 4 5 5 5 
Total75 69 265 50 56 63 96 
Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation
Engineered Materials— — 1 1 — — — 
Acetate Tow— — — — — — — 
Acetyl Chain— — — — — — — 
Other Activities(2)
38 38 16 (67)28 27 28 
Total38 38 17 (66)28 27 28 
Gain (Loss) On Sale of Investments in Affiliates
Engineered Materials— — 1,408 1,408 — — — 
Acetate Tow— — — — — — — 
Acetyl Chain— — — — — — — 
Other Activities(2)
— — — — — — — 
Total— — 1,408 1,408 — — — 
Certain Items Attributable to Celanese Corporation (Table 8)
Engineered Materials6 5 (1,356)(1,404)11 27 10 
Acetate Tow1 4 5 — 1 1 3 
Acetyl Chain(2)30 7 — 5 (3)5 
Other Activities(2)
8 11 128 110 7 3 8 
Total13 50 (1,216)(1,294)24 28 26 
___________________________
(1)Net earnings (loss) attributable to NCI is included within the Acetyl Chain segment.
(2)Other Activities includes corporate SG&A expenses, the results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).
5
Table 2 - Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited (cont.)
celaneseimagea20.jpg
Q2 '21Q1 '212020Q4 '20Q3 '20Q2 '20Q1 '20
(In $ millions, except percentages)
Adjusted EBIT / Adjusted EBIT Margin
Engineered Materials161 23.6 %160 24.8 %403 19.4 %82 14.3 %116 22.1 %40 9.5 %165 29.3 %
Acetate Tow62 44.9 %61 51.3 %249 48.0 %59 44.0 %59 45.7 %64 50.4 %67 51.9 %
Acetyl Chain514 36.5 %282 26.7 %568 18.0 %187 20.5 %126 16.2 %116 17.5 %139 17.4 %
Other Activities(2)
(46)(21)(89)(28)(11)(21)(29)
Total 691 31.4 %482 26.8 %1,131 20.0 %300 18.9 %290 20.6 %199 16.7 %342 23.4 %
Depreciation and Amortization Expense(1)
Engineered Materials34 33 129 32 33 32 32 
Acetate Tow9 10 36 10 9 9 8 
Acetyl Chain43 41 162 41 41 41 39 
Other Activities(2)
4 4 17 4 5 4 4 
Total90 88 344 87 88 86 83 
Operating EBITDA / Operating EBITDA Margin
Engineered Materials195 28.6 %193 29.9 %532 25.6 %114 19.9 %149 28.3 %72 17.1 %197 35.0 %
Acetate Tow71 51.4 %71 59.7 %285 54.9 %69 51.5 %68 52.7 %73 57.5 %75 58.1 %
Acetyl Chain557 39.5 %323 30.6 %730 23.2 %228 25.1 %167 21.5 %157 23.7 %178 22.3 %
Other Activities(2)
(42)(17)(72)(24)(6)(17)(25)
Total781 35.5 %570 31.7 %1,475 26.1 %387 24.3 %378 26.8 %285 23.9 %425 29.1 %
___________________________
(1)Excludes accelerated depreciation and amortization expense, which amounts are included in Certain Items above. See Table 1 for details.
(2)Other Activities includes corporate SG&A expenses, the results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).
6
celaneseimagea20.jpg
Table 3
Adjusted Earnings (Loss) per Share - Reconciliation of a Non-GAAP Measure - Unaudited
Q2 '21Q1 '212020Q4 '20Q3 '20Q2 '20Q1 '20
per shareper shareper shareper shareper shareper shareper share
(In $ millions, except per share data)
Earnings (loss) from continuing operations attributable to Celanese Corporation
542 4.81 323 2.83 1,997 16.85 1,453 12.50 209 1.76 110 0.93 225 1.88 
Income tax provision (benefit)
116 85 247 117 30 35 65 
Earnings (loss) from continuing operations before tax
658 408 2,244 1,570 239 145 290 
Certain Items attributable to Celanese Corporation (Table 8)
13 50 (1,216)(1,294)24 28 26 
Refinancing and related expenses
— — — — — — — 
Adjusted earnings (loss) from continuing operations before tax
671 458 1,028 276 263 173 316 
Income tax (provision) benefit on adjusted earnings(1)
(105)(64)(123)(33)(32)(18)(41)
Adjusted earnings (loss) from continuing operations(2)
566 5.02 394 3.46 905 7.64 243 2.09 231 1.95 155 1.30 275 2.29 
Diluted shares (in millions)(3)
Weighted average shares outstanding
112.3 113.5 117.8 115.7 118.0 118.3 119.3 
Incremental shares attributable to equity awards
0.5 0.5 0.7 0.6 0.6 0.5 0.6 
Total diluted shares112.8 114.0 118.5 116.3 118.6 118.8 119.9 
______________________________
(1)Calculated using adjusted effective tax rates (Table 3a) as follows:
Q2 '21Q1 '212020Q4 '20Q3 '20Q2 '20Q1 '20
(In percentages)
Adjusted effective tax rate
16 14 12 12 12 10 13 
(2)Excludes the immediate recognition of actuarial gains and losses and the impact of actual vs. expected plan asset returns.
Actual Plan Asset ReturnsExpected Plan Asset Returns
(In percentages)
202012.4 6.5 
(3)Potentially dilutive shares are included in the adjusted earnings per share calculation when adjusted earnings are positive.
7
celaneseimagea20.jpg
Table 3a
Adjusted Tax Rate - Reconciliation of a Non-GAAP Measure - Unaudited
EstimatedActual
20212020
(In percentages)
US GAAP annual effective tax rate18 11 
Discrete quarterly recognition of GAAP items(1)
(1)12 
Tax impact of other charges and adjustments(2)
(2)(9)
Utilization of foreign tax credits(1)(3)
Changes in valuation allowances, excluding impact of other charges and adjustments(3)
1 — 
Other(4)
— 1 
Adjusted tax rate15 12 
______________________________
Note: As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate for actual results.
(1)Such as changes in tax laws (including US tax reform), deferred taxes on outside basis differences, changes in uncertain tax positions and prior year audit adjustments.
(2)Reflects the tax impact on pre-tax adjustments presented in Certain Items (Table 8), which are excluded from pre-tax income for adjusted earnings per share purposes.
(3)Reflects changes in valuation allowances related to changes in judgment regarding the realizability of deferred tax assets or current year operations, excluding other charges and adjustments.
(4)Tax impacts related to full-year forecasted tax opportunities and related costs.
8
celaneseimagea20.jpg
Table 4
Net Sales by Segment - Unaudited
Q2 '21Q1 '212020Q4 '20Q3 '20Q2 '20Q1 '20
(In $ millions)
Engineered Materials682 645 2,081 572 526 420 563 
Acetate Tow138 119 519 134 129 127 129 
Acetyl Chain1,409 1,056 3,147 910 776 662 799 
Other Activities— — — — — — — 
Intersegment eliminations(1)
(31)(22)(92)(25)(20)(16)(31)
Net sales2,198 1,798 5,655 1,591 1,411 1,193 1,460 
___________________________
(1)Includes intersegment sales primarily related to the Acetyl Chain.
9
celaneseimagea20.jpg
Table 4a
Factors Affecting Segment Net Sales Sequentially - Unaudited
Three Months Ended June 30, 2021 Compared to Three Months Ended March 31, 2021
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials(1)7 — — 6 
Acetate Tow16 — — — 16 
Acetyl Chain7 27 — — 34 

Total Company4 18 — — 22 
Three Months Ended March 30, 2021 Compared to Three Months Ended December 31, 2020
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials6 6 1 — 13 
Acetate Tow(10)(1)— — (11)
Acetyl Chain(7)23 — — 16 
Total Company(3)15 1 — 13 
Three Months Ended December 31, 2020 Compared to Three Months Ended September 30, 2020
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials7 — 2 — 9 
Acetate Tow4 (1)— — 3 
Acetyl Chain6 10 1 — 17 
Total Company7 5 1 — 13 
Three Months Ended September 30, 2020 Compared to Three Months Ended June 30, 2020
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials27 (6)4 — 25 
Acetate Tow1 1 1 — 3 
Acetyl Chain18 (2)1 — 17 
Total Company20 (3)2 (1)18 


Three Months Ended June 30, 2020 Compared to Three Months Ended March 31, 2020
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials(25)— — — (25)
Acetate Tow(3)1 — — (2)
Acetyl Chain(6)(11)— — (17)
(1)
Total Company(13)(6)— 1 (18)
Three Months March 31, 2020 Compared to Three Months Ended December 31, 2019
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials4 — — — 4 
Acetate Tow(9)(4)— — (13)
Acetyl Chain5 (1)— — 4 
Total Company3 (1)— — 2 
________________________
(1)2020 includes the effect of the acquisition of the Elotex® brand.
10
celaneseimagea20.jpg
Table 4b
Factors Affecting Segment Net Sales Year Over Year - Unaudited
Three Months Ended June 30, 2021 Compared to Three Months Ended June 30, 2020
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials43 11 8 — 62 
Acetate Tow10 (1)— — 9 
Acetyl Chain27 83 3 — 113 
Total Company31 50 4 (1)84 
Three Months Ended March 31, 2021 Compared to Three Months Ended March 31, 2020
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials7 2 6 — 15 
Acetate Tow(8)— — — (8)
Acetyl Chain5 25 2 — 32 
Total Company5 14 4 — 23 
Three Months Ended December 31, 2020 Compared to Three Months Ended December 31, 2019
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials6 (4)4 — 6 
Acetate Tow(7)(3)1 — (9)
Acetyl Chain19 (3)2 — 18 
Total Company12 (4)3 — 11 
Three Months Ended September 30, 2020 Compared to Three Months Ended September 30, 2019
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials(10)(3)2 — (11)
Acetate Tow(15)(3)— — (18)
Acetyl Chain(1)(11)1 — (11)
Total Company(6)(7)1 1 (11)


Three Months Ended June 30, 2020 Compared to Three Months Ended June 30, 2019
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials(27)(1)(1)— (29)
Acetate Tow(18)(5)— — (23)
Acetyl Chain(14)(8)(1)— (23)
Total Company(20)(5)(1)1 (25)
Three Months March 31, 2020 Compared to Three Months Ended March 31, 2019
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials(9)(5)(1)— (15)
Acetate Tow(17)(5)— — (22)
Acetyl Chain(3)(7)(1)1 (10)
Total Company(7)(6)(1)1 (13)
11
celaneseimagea20.jpg
Table 4c
Factors Affecting Segment Net Sales Year Over Year - Unaudited
Year Ended December 31, 2020 Compared to Year Ended December 31, 2019
VolumePriceCurrencyOtherTotal
 (In percentages)
Engineered Materials(11)(3)1 — (13)
Acetate Tow(14)(4)— — (18)
Acetyl Chain— (8)1 — (7)
Total Company(5)(6)— 1 (10)
12
celaneseimagea20.jpg
Table 5
Free Cash Flow - Reconciliation of a Non-GAAP Measure - Unaudited
Q2 '21Q1 '212020Q4 '20Q3 '20Q2 '20Q1 '20
(In $ millions, except percentages)
Net cash provided by (used in) investing activities177 98 592 979 (78)(181)(128)
Net cash provided by (used in) financing activities(344)(371)(1,471)(933)(290)(232)(16)
Net cash provided by (used in) operating activities427 116 1,343 274 431 379 259 
Capital expenditures on property, plant and equipment(110)(92)(364)(85)(72)(88)(119)
Distributions to NCI(8)(5)(29)(8)(8)(8)(5)
Free cash flow(1)(2)
309 19 950 181 351 283 135 
Net sales2,198 1,798 5,655 1,591 1,411 1,193 1,460 
Free cash flow as % of Net sales14.1 %1.1 %16.8 %11.4 %24.9 %23.7 %9.2 %
______________________________
(1)Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operating activities, less capital expenditures on property, plant and equipment, and adjusted for capital contributions or distributions to Mitsui related to our joint venture, Fairway.
(2)Excludes required debt service and finance lease payments of $30 million and $26 million for the years ended December 31, 2021 and 2020, respectively.
13
celaneseimagea20.jpg
Table 6
Cash Dividends Received - Unaudited
Q2 '21Q1 '212020Q4 '20Q3 '20Q2 '20Q1 '20
(In $ millions)
Dividends from equity method investments18 35 147 36 6 59 46 
Dividends from equity investments without readily determinable fair values37 42 126 28 29 32 37 
Total55 77 273 64 35 91 83 
Table 7
Net Debt - Reconciliation of a Non-GAAP Measure - Unaudited
Q2 '21Q1 '212020Q4 '20Q3 '20Q2 '20Q1 '20
(In $ millions)
Short-term borrowings and current installments of long-term debt - third party and affiliates
500 497 496 496 958 1,045 749 
Long-term debt, net of unamortized deferred financing costs3,156 3,135 3,227 3,227 3,140 2,989 3,356 
Total debt3,656 3,632 3,723 3,723 4,098 4,034 4,105 
Cash and cash equivalents(1,054)(791)(955)(955)(615)(539)(570)
Net debt2,602 2,841 2,768 2,768 3,483 3,495 3,535 
14
celaneseimagea20.jpg
Table 8
Certain Items - Unaudited
The following Certain Items attributable to Celanese Corporation are included in Net earnings (loss) and are adjustments to non-GAAP measures:
Q2 '21Q1 '212020Q4 '20Q3 '20Q2 '20Q1 '20Income Statement Classification
(In $ millions)
Plant/office closures3 (5)10 7 4 (4)3 Cost of sales / SG&A / Other (charges) gains, net / Gain (loss) on disposition of businesses and assets, net
Asset impairments1 1 31 — 2 25 4 
Cost of sales / Other (charges) gains, net
Clear Lake incident— — 4 — — — 4 Cost of sales
COVID-19— — 5 2 1 1 1 Cost of sales / SG&A
Mergers, acquisitions and dispositions6 — 22 5 7 3 7 Cost of sales / SG&A
Impact from natural disasters
— 41 — — — — — Cost of sales
Actuarial (gain) loss on pension and postretirement plans
— — 95 95 — — — Cost of sales / SG&A / Non-operating pension and other postretirement employee benefit (expense) income
Restructuring2 3 25 5 11 2 7 SG&A / Other (charges) gains, net / Non-operating pension and other postretirement employee benefit (expense) income
European Commission investigation— — 2 — — 2 — Other (charges) gains, net
Commercial disputes1 9 (1)— — (1)— Cost of sales / SG&A / Other (charges) gains, net
(Gain) loss on sale of investments in affiliates— — (1,408)(1,408)— — — Gain (loss) on sale of investments in affiliates
Other— 1 (1)— (1)— — SG&A / Gain (loss) on disposition of businesses and assets, net
Certain Items attributable to Celanese Corporation
13 50 (1,216)(1,294)24 28 26 
15
celaneseimagea20.jpg
Table 9
Return on Invested Capital (Adjusted) - Presentation of a Non-GAAP Measure - Unaudited
2020
(In $ millions, except percentages)
Net earnings (loss) attributable to Celanese Corporation1,985 
Adjusted EBIT (Table 1)
1,131 
Adjusted effective tax rate (Table 3a)
12 %
Adjusted EBIT tax effected995 
20202019Average
(In $ millions, except percentages)
Short-term borrowings and current installments of long-term debt - third parties and affiliates
496 496 496 
Long-term debt, net of unamortized deferred financing costs3,227 3,409 3,318 
Celanese Corporation stockholders' equity3,526 2,507 3,017 
Invested capital6,831 
Return on invested capital (adjusted)14.6 %
Net earnings (loss) attributable to Celanese Corporation as a percentage of invested capital
29.1 %
16